Oak Associates Ltd. OH Boosts Stake in Zimmer Biomet Holdings, Inc. $ZBH

Oak Associates Ltd. OH lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 89,935 shares of the medical equipment provider’s stock after buying an additional 3,720 shares during the period. Oak Associates Ltd. OH’s holdings in Zimmer Biomet were worth $8,203,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Accent Capital Management LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter worth $35,000. Zions Bancorporation National Association UT bought a new stake in Zimmer Biomet in the first quarter worth about $48,000. Hilltop National Bank bought a new stake in Zimmer Biomet in the second quarter worth about $42,000. Brooklyn Investment Group boosted its stake in Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares during the last quarter. Finally, True Wealth Design LLC grew its position in shares of Zimmer Biomet by 875.0% during the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 420 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $93.54 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.44. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $18.54 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The firm’s 50 day simple moving average is $97.02 and its 200 day simple moving average is $96.78.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the business earned $1.74 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Royal Bank Of Canada decreased their price objective on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Stifel Nicolaus set a $110.00 price objective on shares of Zimmer Biomet in a report on Wednesday, November 5th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $109.00.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.